Ototoxic Medications: What to Ask Your Doctor About

What "Ototoxic" Actually Means

Ototoxicity refers to damage to the inner ear, specifically the cochlea (hearing) and, in some cases, the vestibular system (balance), caused by exposure to a medication or chemical. The National Institute on Deafness and Other Communication Disorders defines ototoxic drugs simply as medications that can damage the hearing or balance organs of the inner ear for some people who take them. ^[1]

It's worth being clear about what this doesn't mean. Most medications with documented ototoxic risk are prescribed for serious conditions, life-threatening infections, cancer, heart failure, kidney disease, where the benefit of treatment substantially outweighs the risk to hearing for most patients. ^[2] The goal of understanding ototoxicity isn't to second-guess a doctor's prescribing decision, it's to know what questions are worth asking and what symptoms are worth reporting promptly if you're on one of these medications.

Medications With Documented Ototoxic Risk

A number of distinct drug classes carry documented, well-studied ototoxic risk. Risk and reversibility vary considerably between them, which is covered in more detail further down.

• Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin, streptomycin). These are typically reserved for serious bacterial infections, including sepsis and drug-resistant tuberculosis, precisely because they're effective against organisms other antibiotics can't reach. They damage the sensory hair cells of the cochlea through oxidative stress and programmed cell death, and the resulting hearing loss is usually permanent. ^[3]
• Platinum-based chemotherapy agents, most notably cisplatin. Cisplatin ototoxicity is common enough in cancer treatment that baseline hearing testing before treatment starts is considered clinically important, since it establishes what "normal" looked like for that patient before any changes appear. ^[4]
• Loop diuretics (furosemide, bumetanide, ethacrynic acid), used for fluid overload in heart failure and kidney disease. These act on the stria vascularis, the tissue that helps generate the electrical potential the cochlea depends on, and hearing changes are usually reversible, though permanent cases have been reported, particularly with high intravenous doses or when combined with other ototoxic drugs. ^[5]
• High-dose aspirin and salicylates, and, less consistently, other NSAIDs. Ototoxicity here is dose-dependent, tinnitus and mild hearing loss are the hallmark symptoms, and both typically resolve within days of stopping or reducing the dose. ^[6]
• Antimalarials (quinine, chloroquine, and related compounds). Quinine-related hearing changes are usually transient, often resolving within a day to a week, while chloroquine has been reported to cause more abrupt hearing loss in some cases. Reversibility is the more common outcome for both, but it isn't universal. ^[7]

Reversible vs. Irreversible: What the Difference Depends On

Whether ototoxic hearing changes recover depends on the drug involved, the dose and duration of exposure, kidney function (since impaired clearance lets drug levels build up), whether multiple ototoxic medications are combined, and individual susceptibility, including a known genetic mitochondrial variant that makes some people dramatically more vulnerable to aminoglycoside damage even at standard doses. ^[2]

As a general pattern, aminoglycoside antibiotics and platinum-based chemotherapy tend to cause permanent damage, since both work by killing the cochlea's sensory hair cells outright, and those cells don't regenerate in humans. ^[3] Cisplatin-related hearing loss can also be a slow-moving target: longitudinal follow-up has documented new hearing changes appearing years after treatment ended, in one analysis as long as roughly eleven years later, which is part of why ongoing monitoring after treatment stops still matters. ^[4]

Loop diuretics, salicylates, and quinine-class antimalarials sit on the more reversible end of the spectrum, with hearing typically returning to baseline after the drug is reduced or stopped, though none of these classes are reversible with absolute certainty in every patient. ^{[5] [6] [7]} This is why reporting symptoms early, rather than waiting to see if they pass, gives a doctor the best chance to adjust course while a reversible pattern is still likely.

How Doctors Monitor for Ototoxicity

For medications with well-established ototoxic risk, particularly cisplatin and long courses of IV aminoglycosides, formal monitoring protocols exist. The American Speech-Language-Hearing Association's guidance calls for a baseline hearing assessment before treatment starts whenever feasible, followed by monitoring visits at intervals appropriate to the treatment schedule, and post-treatment follow-up rather than assuming risk ends when the last dose does. ^[8]

Monitoring typically combines standard pure-tone audiometry with extended high-frequency audiometry, since ototoxic damage often shows up first at frequencies above the range covered by a routine hearing test, along with otoacoustic emissions testing and, in some protocols, patient-reported symptom checklists between formal visits. ^[2] This kind of monitoring generally involves a prescribing physician, a pharmacist tracking drug levels and interactions, and an audiologist, working together rather than any one of them handling it alone.

Beyond a specific treatment course, keeping a general sense of your own hearing baseline is useful groundwork, especially since age-related hearing changes can make it harder to notice a new, medication-related shift against an already-changing background.

Questions to Ask Before and During Treatment

If you're being prescribed a medication with known ototoxic risk, a short conversation up front can make monitoring far more effective. Consider asking:

• "Is this medication known to carry ototoxic risk, and how does that weigh against the benefit for my specific condition?" Context matters enormously here; a short aminoglycoside course for a serious infection is a very different calculation than a comparable drug used electively.
• "Should I have a baseline hearing test before we start, and how often should it be repeated during treatment?" This is especially relevant for planned chemotherapy or extended IV antibiotic courses.
• "Are any of my other medications ototoxic on their own, or more risky in combination with this one?" Combining a loop diuretic with an aminoglycoside, for example, is a recognized higher-risk pairing worth flagging explicitly. ^[5]
• "Does my kidney function need to be monitored alongside my hearing?" Reduced clearance can let ototoxic drugs build up to higher levels than intended.
• "What symptoms should prompt me to call you, rather than wait for my next scheduled visit?"

None of these questions are about refusing necessary treatment, they're about making sure monitoring happens on purpose rather than by accident.

A Gentle Wellness Routine, After the Safety Checks

Your prescriber and pharmacist come first on medication questions, and nothing here changes that. Once you have talked through your medications, some people like to add a daily hearing-wellness habit, and Audifort is designed to support healthy hearing. Ask your pharmacist whether any supplement suits your regimen, and use the 90-day money-back guarantee to try it risk-free.

See Audifort and the 90-day guarantee →